How Does Vijaya ( Hemp ) Work In The Body ?

How Does Vijaya ( Hemp ) Work In The Body ?

As mentioned in our previous blog, the Vijaya plant leaf contains hundreds of compounds. Two of them, cannabidiol (CBD) and tetrahydrocannabinol (THC) bind to the receptors CB2-R and CB1-R. Both have medical benefits, but only THC is known to produce euphoric effects.

Full spectrum Vijaya leaf extract contains minor cannabinoids as well that interact with the endocannabinoid system, but their effects are weaker and they are found in lower concentrations.

Read More:- Managing Asthma Naturally: The Promise of CBD Oil

Medicines can target the ECS therapeutically in 2 ways:

1. The active drug compound in the medicine can bind to the CB1-R and CB2-R and stimulate their activity like CBD. Such compounds are known as cannabinoid receptor agonists.
2. Cannabinoid receptor antagonists are used to suppress cannabinoid receptor activity. For example, rimonabant

References:

1. Raypole , C. A Simple Guide to the Endocannabinoid System. Healthline. Weblog. [Online] Availablefrom: https://www.healthline.com/health/endocannabinoid-system#how-it-works [Accessed 2 July 2021].
2. Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical research, 30(8), 1037–1043. https://doi.org/10.1007/s11064-005-6978-1
3. Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., Guan, Y., Pan, H. L., Ren, K., Xu, Y., & Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of experimental medicine, 209(6), 1121–1134. https://doi.org/10.1084/jem.20120242
4. Seeman P. (2016). Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry, 6(10), e920. https://doi.org/10.1038/tp.2016.195
5. Ibeas Bih, C., Chen, T., Nunn, A. V., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 699–730. https://doi.org/10.1007/s13311-015-0377-3
6. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1
7. Du, H., Chen, X., Zhang, J., & Chen, C. (2011). Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. British journal of pharmacology, 163(7), 1533–1549. https://doi.org/10.1111/j.1476-5381.2011.01444.x
8. Sharir, H., & Abood, M. E. (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacology & therapeutics, 126(3), 301–313. https://doi.org/10.1016/j.pharmthera.2010.02.004
9. McPartland, J. M., Agraval, J., Gleeson, D., Heasman, K., & Glass, M. (2006). Cannabinoid receptors in invertebrates. Journal of evolutionary biology, 19(2), 366–373. https://doi.org/10.1111/j.1420-9101.2005.01028.x